18th Oct 2016 07:00
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||||||
a) | Name | Sir Andrew Witty | ||||||||||||||||||||||
b) | Position/status | Chief Executive Officer | ||||||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||
d) | Aggregated information Aggregated volume Price |
3155.638 £17.00
| ||||||||||||||||||||||
e) | Date of the transaction | 2016-10-13 | ||||||||||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||||||||||
a) | Name | Ms E Walmsley | ||||||||||||||||||||||||||
b) | Position/status | CEO Designate | ||||||||||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||||||
d) | Aggregated information Aggregated volume Price |
1224.146 £17.00
| ||||||||||||||||||||||||||
e) | Date of the transaction | 2016-10-13 | ||||||||||||||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||||||
a) | Name | Mr R G Connor | ||||||||||||||||||||||
b) | Position/status | President, Global Manufacturing & Supply | ||||||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||
d) | Aggregated information Aggregated volume Price |
697.320 £17.00
| ||||||||||||||||||||||
e) | Date of the transaction | 2016-10-13 | ||||||||||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||||||||||
a) | Name | Mr S Dingemans | ||||||||||||||||||||||||||
b) | Position/status | Chief Financial Officer | ||||||||||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||||||
d) | Aggregated information Aggregated volume Price |
1697.968 £17.00
| ||||||||||||||||||||||||||
e) | Date of the transaction | 2016-10-13 | ||||||||||||||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||
a) | Name | Mr N Hirons | ||||||||||||||||||
b) | Position/status | SVP, Global Ethics & Compliance | ||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||
d) | Aggregated information Aggregated volume Price |
445.596 £17.00
| ||||||||||||||||||
e) | Date of the transaction | 2016-10-13 | ||||||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||
a) | Name | Mr S A Hussain | ||||||||||||||||||
b) | Position/status | President, Global Pharmaceuticals | ||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||
d) | Aggregated information Aggregated volume Price |
1264.948 £17.00
| ||||||||||||||||||
e) | Date of the transaction | 2016-10-13 | ||||||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||||||||||
a) | Name | Mr D S Redfern | ||||||||||||||||||||||||||
b) | Position/status | Chief Strategy Officer | ||||||||||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||||||
d) | Aggregated information Aggregated volume Price |
875.454 £17.00
| ||||||||||||||||||||||||||
e) | Date of the transaction | 2016-10-13 | ||||||||||||||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||||||||||
a) | Name | Dr M M Slaoui | ||||||||||||||||||||||||||
b) | Position/status | Chairman, Global Vaccines | ||||||||||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||||||||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| ||||||||||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||||||
d) | Aggregated information Aggregated volume Price |
1220.178 $42.39
| ||||||||||||||||||||||||||
e) | Date of the transaction | 2016-10-13 | ||||||||||||||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||||||
a) | Name | Ms C Thomas | ||||||||||||||||||||||
b) | Position/status | SVP, Human Resources | ||||||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||
d) | Aggregated information Aggregated volume Price |
1032.946 £17.00
| ||||||||||||||||||||||
e) | Date of the transaction | 2016-10-13 | ||||||||||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||
a) | Name | Mr P C Thomson | ||||||||||||||
b) | Position/status | SVP, Communications & Government Affairs | ||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||
d) | Aggregated information Aggregated volume Price |
374.292 £17.00
| ||||||||||||||
e) | Date of the transaction | 2016-10-13 | ||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||||||||||
a) | Name | Mr D E Troy | ||||||||||||||||||||||||||
b) | Position/status | SVP & General Counsel | ||||||||||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||||||||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| ||||||||||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||||||
d) | Aggregated information Aggregated volume Price |
669.344 $42.39
| ||||||||||||||||||||||||||
e) | Date of the transaction | 2016-10-13 | ||||||||||||||||||||||||||
f) | Place of the transaction
| n/a |
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||||||||||||||||||
a) | Name | Dr P J T Vallance | ||||||||||||||||||||||||||
b) | Position/status | President, Pharmaceuticals R&D | ||||||||||||||||||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||||||||||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||||||||||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||||||||||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||||||||||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||||||||||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. | ||||||||||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||||||||||
d) | Aggregated information Aggregated volume Price |
1693.318 £17.00
| ||||||||||||||||||||||||||
e) | Date of the transaction | 2016-10-13 | ||||||||||||||||||||||||||
f) | Place of the transaction
| n/a |
Related Shares:
Glaxosmithkline